[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain

Inclusion Criteria: * 1\. Patients with suspicious brain gliomas: * Patients diagnosed by the investigator, based on symptoms, course of disease, and MRI of the head, as having a suspected high- or low-grade brain glioma, scheduled for brain tumor resection, and with no contraindications to surgery; * No prior and/or current surgery, radiotherapy, or puncture biopsy (other than treatment for symptomatic relief) for brain tumors; * No other primary malignant tumor. 2. age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) 0-2; 4. adequate organ function: * Platelet count \>100 x 109/L; * Urea/urea nitrogen and serum creatinine \<1.5 times upper limit of normal (ULN); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times ULN. 5\. Subjects should be fully informed of the content, process and possible risks of the test and voluntarily sign an informed consent form. Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from the study: 1. Severe allergic reaction to any of the drugs or their components in this trial; 2. Those who cannot tolerate or are contraindicated to undergo MRI and PET; 3. Those who cannot accept or tolerate blood sample collection; 4. Those who are unable to use effective contraception from the date of signing the informed consent to 3 months after the administration of the drug; 5. pregnant or lactating women or those with positive blood pregnancy test results; 6. Those who have participated in other interventional clinical trials prior to the date of informed consent and are within 5 half-lives of the trial drug, or are participating in other interventional clinical trials;